

Press Release

Change of Directors

TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 19th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 20, 2024.

1. Candidates for Directors (excluding Directors who Are Audit & Supervisory Committee Members)

Name		Current Position
Kenji Yasukawa	Reelection	Representative Director, Chairman of the Board
Naoki Okamura	Reelection	Representative Director, President and CEO
Katsuyoshi Sugita	Reelection	Representative Director, Executive Vice President, Chief People Officer and Chief Ethics & Compliance Officer
Takashi Tanaka	Outside Reelection	Representative Director, Chairman of the Board, KDDI CORPORATION Director, Okinawa Cellular Telephone Company
Eriko Sakurai	Outside Reelection	Outside Director, Sumitomo Mitsui Financial Group, Inc. Outside Director, Kao Corporation Outside Director, Nippon Sheet Glass Company, Ltd
Masahiro Miyazaki	Outside Reelection	Outside Director, Kurita Water Industries Ltd.
Yoichi Ohno	Outside Reelection	Visiting Professor, Social Medicine, Research Administration Center and Medical Education Center, Saitama Medical University

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

2. Candidates for Directors who Are Audit & Supervisory Committee Members

Name		Current Position
Rika Hirota	New Candidate	Report to CEO
Mika Nakayama	Outside Reelection	
Tomoko Aramaki	Outside New Candidate	President, Aramaki CPA Office Outside Director, FUJI SOFT INCORPORATED Outside Director, EXEO Group, Inc. Outside Director, Audit & Supervisory Committee Member, TRE HOLDINGS CORPORATION

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

3. Directors to Be Retired

Director, Audit & Supervisory Committee Member Toru Yoshimitsu
 Outside Director, Audit & Supervisory Committee Member Raita Takahashi

4. The Board of Directors as from June 20, 2024 (planned)

Kenji Yasukawa (Representative Director, Chairman of the Board)
 Naoki Okamura (Representative Director, President and CEO)
 Katsuyoshi Sugita (Representative Director, Executive Vice President)
 Takashi Tanaka (Outside Director)
 Eriko Sakurai (Outside Director)
 Masahiro Miyazaki (Outside Director)
 Yoichi Ohno (Outside Director)
 Rika Hirota (Director, Audit & Supervisory Committee Member)
 Mika Nakayama (Outside Director, Audit & Supervisory Committee Member)
 Rie Akiyama (Outside Director, Audit & Supervisory Committee Member)
 Tomoko Aramaki (Outside Director, Audit & Supervisory Committee Member)

(Reference)

- Brief Biographies of New Candidates for Director, Audit & Supervisory Committee Member

Name: Rika Hirota

Date of birth: December 18, 1966

Resume, position and responsibilities at the Company:

April 1991	Joined the Company
April 2015	Head, Bioscience Research Laboratories, Drug Discovery Research, the Company
April 2017	Head, Research Regulatory Management, Drug Discovery Research, the Company
April 2022	Head, Research Regulation and Administration, Applied Research and Operations, the Company
January 2023	Special Advisor, Audit & Supervisory Committee Office, the Company
April 2023	Head, Audit & Supervisory Committee Office, the Company
April 2024	Report to CEO, the Company (present post)

Name: Tomoko Aramaki

Date of birth: November 7, 1968

Resume, position and responsibilities at the Company:

October 1991	Joined Century Audit Corporation (current Ernst & Young ShinNihon LLC) (resigned in October 2001)
March 1995	Registered as Certified Public Accountant
February 2006	President, Aramaki CPA Office (present post)
April 2006	Registered as Certified Tax Accountant
June 2008	Outside Audit & Supervisory Board Member, PARIS MIKI HOLDINGS Inc.
June 2015	Director, in charge of Investor Relations, PARIS MIKI HOLDINGS Inc.
December 2015	Outside Audit & Supervisory Board Member, SACOS CORPORATION
June 2018	Outside Audit & Supervisory Board Member, KYOWA EXEO CORPORATION (current EXEO Group, Inc.)
March 2022	Outside Director, FUJI SOFT INCORPORATED (present post)
June 2023	Outside Director, EXEO Group, Inc. (present post)
June 2023	Outside Director (Audit & Supervisory Committee Member), TRE HOLDINGS CORPORATION (present post)

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201